KYTX
Kyverna Therapeutics Inc. · NASDAQ
- Market cap
- $300.9M
Kyverna Therapeutics Inc. (KYTX) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 9 wire items for KYTX, including 5 press releases and news items, 2 SEC filings and 1 earnings update. The most recent was published Nov 16, 2026.
KYTX rankings
Financial highlights
Full financials- Net income, TTM
- -$157.79M
- Cash
- $31.82M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks28+50%
2026-05-242026-11-15
Mix1390d
- Other7(54%)
- SEC Filings3(23%)
- Earnings2(15%)
- 13D/G1(8%)
Activity · 52 weeks9251 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by Kyverna Therapeutics Inc.SCHEDULE 13G/A - Kyverna Therapeutics, Inc. (0001994702) (Subject)
- SECSEC Form 10-Q filed by Kyverna Therapeutics Inc.10-Q - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- SECKyverna Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- PRKyverna Therapeutics Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and Reports Third Quarter 2026 Financial ResultsBLA submission for miv-cel in SPS completed with request for priority review Commercial readiness advancing for potential U.S. launch of miv-cel, which would become the first approved therapy for SPS and first approved CAR-T therapy in autoimmune disease KYSA-6 Phase 3 gMG trial enrollment on-track for completion in mid-2027Miv-cel’s clinical profile continues to set the benchmark for autoimmune CAR T, demonstrating durable clinical benefit and a consistent, well-tolerated safety profile across multiple neurologic autoimmune indications EMERYVILLE, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical immunology company pioneering tr
- PRKyverna Therapeutics Announces Publication of Registrational Miv-cel Data in Patients with Stiff Person Syndrome in JAMA NeurologyPublication reinforces miv-cel's potential to deliver durable clinical benefit with a single dose, enabled by miv-cel's unique construct, and become the first approved therapy in SPS and first approved CAR T-cell therapy for autoimmune disease Initially presented at AAN, the primary analysis measured at 16 weeks demonstrated statistically significant improvements across all primary and secondary endpoints, including mobility and disability, with patients no longer requiring chronic immunotherapies Consistent, well-tolerated safety profile with no high-grade CRS or ICANS, and no cases of IEC-HS EMERYVILLE, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYT
- PRKyverna Therapeutics to Present at the Jefferies London Healthcare ConferenceEMERYVILLE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced that company management will present at the Jefferies Global Healthcare Conference in London, United Kingdom on Thursday, November 19, 2026, at 10:00 am GMT. A live webcast of the presentation may be accessed via the Investors section of the Kyverna website at ir.kyvernatx.com. A replay of the webcast will be available on the website for approximately 90 days following the conference. About Kyverna Therapeutics Kyverna Therapeutics, Inc. (NASDAQ:KYTX) i
- PRKyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026Single-dose miv-cel continues to demonstrate promising clinical benefit in progressive multiple sclerosis, achieving robust CAR T-cell penetration in the central nervous system (CNS) and improving disability scores while removing the need for chronic immunotherapies Durable results extending beyond two years in the first patient treated Consistent, well-tolerated safety profile with no high-grade CRS and no cases of ICANS or IEC-HS RMAT designation granted in treatment of non-active secondary progressive multiple sclerosis (naSPMS); update on development strategy expected by early 2027 EMERYVILLE, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a lat
- PRKyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS TorontoMiv-cel reversed disability and achieved durable efficacy across all primary and secondary endpoints through one year, with nearly all patients remaining off chronic immunotherapies Deep B-cell depletion demonstrated with a single dose supports the potential for broad immune reset enabled by miv-cel's unique construct Consistent, well-tolerated safety profile with no high-grade CRS or ICANS, and no cases of IEC-HS in one-year follow-up Data further strengthens SPS BLA package and supports potential for miv-cel to be the first approved therapy in SPS and first approved CAR T-cell therapy for autoimmune diseases EMERYVILLE, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics,
- SECSEC Form SCHEDULE 13G filed by Kyverna Therapeutics Inc.SCHEDULE 13G - Kyverna Therapeutics, Inc. (0001994702) (Subject)
- PRKyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026Full one-year results from the KYSA-8 registrational trial in stiff person syndrome to be reported, demonstrating sustained clinical benefit and a well-tolerated safety profile with no high-grade CRS or ICANS and no cases of IEC-HS Updated Phase 1 investigator-initiated trial data to be presented, continuing to highlight encouraging clinical activity and a well-tolerated safety profile in progressive multiple sclerosis EMERYVILLE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced two abstracts selected for present
- SECKyverna Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- PRKyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia GravisTopline durability data reinforce potential for single-dose miv-cel to free patients from life-long disease burden and chronic immunotherapies, further highlighting miv-cel’s differentiated construct Sustained clinical benefit and reversal of disability through one year support the potential to be the first approved therapy in SPS and first approved CAR T-cell therapy for autoimmune disease; rolling BLA submission on track for completion in Q4 2026 Longer-term Phase 2 follow-up in gMG demonstrate robust and durable effects sustained for up to 1.5 years, with majority of patients maintaining MSE; Phase 3 enrollment expected to be completed in mid-2027 Consistent, well-tolerated safety pro
- PRKyverna Therapeutics to Present at Upcoming Investor ConferencesEMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced that company management will present at the following upcoming conferences: 2026 Wells Fargo Healthcare ConferenceFormat: Fireside chat and investor meetingsDate: Wednesday, September 9th, 2026Time: 4:30 p.m. ET Morgan Stanley 24th Annual Global Healthcare ConferenceFormat: Fireside chat and investor meetingsDate: Monday, September 14th, 2026Time: 4:05 p.m. ET H.C. Wainwright 28th Annual Global Investment ConferenceFormat: Fireside chat and investor mee
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Kyverna Therapeutics Inc.SCHEDULE 13G/A - Kyverna Therapeutics, Inc. (0001994702) (Subject)
- SECSEC Form 10-Q filed by Kyverna Therapeutics Inc.10-Q - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- SECKyverna Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- PRKyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial ResultsFDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further expanding the therapy’s potential across neuroimmunology On track to complete rolling BLA submission for miv-cel in stiff person syndrome (SPS) in Q4 2026; KYSA-8 12-month topline data expected in Q3 2026 Enrollment in KYSA-6 Phase 3 trial in generalized myasthenia gravis (gMG) expected to be completed in mid-2027; longer-term follow-up Phase 2 topline data expected in Q3 2026 Reiterates operating runway into 2028 EMERYVILLE, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical immunology
- SECKyverna Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- PRKyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-celEMERYVILLE, Calif., and WALTHAM, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, and ElevateBio, a technology-driven advanced therapy contract development and manufacturing organization (CDMO), today announced a manufacturing agreement for both U.S. commercial and global clinical supply of miv-cel (mivocabtagene autoleucel), Kyverna’s autologous CD19-directed CAR T-cell therapy. The new agreement provides Kyverna with flexible and scalable supply of miv-cel, supporting the Company’s potential launches in stiff person syndrome (SPS) and general
- SECKyverna Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- PRKyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage TransitionEMERYVILLE, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointment of Ritesh Srivastava as Chief Legal and Compliance Officer, effective June 22, 2026. Mr. Srivastava brings extensive experience spanning legal, corporate strategy, compliance, and risk management, which will further support Kyverna as it advances miv-cel (mivocabtagene autoleucel, KYV-101) towards a potential first approval in stiff person syndrome and transitions to a commercial-stage organization. "Ritesh is a key addition to Kyverna as we prepare fo
- PRKyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid ArthritisMajority of patients met the American College of Rheumatology improvement criteria (ACR70) response by Week 36 Single-dose of miv-cel delivered deep B-cell depletion with evidence of immune reset Miv-cel continues to demonstrate a well-tolerated safety profile, consistent with observations from over 100 patients treated to date1 Data reinforce miv-cel's differentiated clinical profile and opportunity to change the treatment paradigm across a variety of autoimmune diseases EMERYVILLE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases,
- SECKyverna Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- INSIDERDirector Cohen Fred E was granted 5,093 shares, increasing direct ownership by 31% to 21,727 units (SEC Form 4)4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
- INSIDERDirector Clark Ian T was granted 5,093 shares, increasing direct ownership by 31% to 21,727 units (SEC Form 4)4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
KYTX FAQ
9 questionsWhat is the latest news on KYTX?
In the last 30 days Quantisnow tracked 9 wire items for KYTX: 5 press releases and news items, 2 SEC filings, 1 earnings update and 1 13D/G filing. The most recent was published on November 16, 2026.Is KYTX profitable?
No. Kyverna Therapeutics Inc. reported a net loss of $157.79M for the twelve months ended Sep 30, 2026.How much cash and debt does KYTX have?
Kyverna Therapeutics Inc. reported $31.82M in cash and cash equivalents and $24.96M of debt on its most recent balance sheet in SEC filings.Where does KYTX stock trade?
Kyverna Therapeutics Inc. (KYTX) is listed on NASDAQ.What sector and industry is KYTX in?
Kyverna Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Kyverna Therapeutics Inc. go public?
Kyverna Therapeutics Inc. (KYTX) completed its IPO in 2024.What are analysts saying about KYTX?
Across the last 8 analyst actions on Kyverna Therapeutics Inc., there was 1 upgrade and 0 downgrades. The most recent action was from William Blair: Outperform on 2025-08-20.What companies are similar to KYTX?
Notable peers in the same industry include MRNA (Moderna Inc.), GILD (Gilead Sciences Inc.), BIIB (Biogen Inc.), RVMD (Revolution Medicines Inc.), AMGN (Amgen Inc.). Compare KYTX side-by-side with any of them on Quantisnow.How can I track KYTX on Quantisnow?
Quantisnow aggregates Kyverna Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KYTX to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change